Drug Trial Radar · NCT06428487
Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 31, 2022
Primary completion
Dec 31, 2024
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Blokhin's Russian Cancer Research CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this phase II study patients with stage II-III MSI/dMMR colorectal adenocarcinoma with no signs of distant metastases will be treated with immunotherapy (prolgolimab). The duration of treatment is 6 months (12 cycles)
Conditions
- Colorectal Cancer
Interventions
ProlgolimabDrug
Prolgolimab infusions 1 mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response (pCR)Time frame: up to 8 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
N.N. Blokhin NMRCO
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.